Vertex Pharmaceuticals Inc VRTX:NASDAQ

Set AlertOptionsStreaming Charts
Last Price$173.59NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/14/19

Today's Change+1.18(0.68%)
Bid (Size)$173.75 (1)
Ask (Size)$175.00 (2)
Day Low / High$172.32 - 175.25
Volume579.6 K
Sell
Buy
Chart Style Historical Chart Icon Download historical data
 

View Biotechnology IndustryPeer Comparison as of 10/14/2019

Timeframe
 

Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $173.59
Change: +1.18 (0.68%)
Volume: 579.6 K
4:00PM ET 10/14/2019
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Illumina Inc ( NASDAQ )

Price: $310.31
Change: +7.73 (2.55%)
Volume: 766.8 K
4:00PM ET 10/14/2019
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Biogen Inc ( NASDAQ )

Price: $225.76
Change: +2.55 (1.14%)
Volume: 3.0 M
4:00PM ET 10/14/2019
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $305.44
Change: +4.67 (1.55%)
Volume: 850.4 K
4:00PM ET 10/14/2019
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain
 

Agilent Technologies Inc ( NYSE )

Price: $75.17
Change: -0.01 (0.01%)
Volume: 845.4 K
4:00PM ET 10/14/2019
 
Sell
Buy
Detailed Quote|Set Alert|Options Chain

Read more news Recent News

Research Alert: CFRA Raises Opinion On Shares Of Vertex Pharmaceuticals, Inc. To Buy From Hold
2:15PM ET 10/09/2019 MT Newswires

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...

Insider Trends: Selling By Insiders Lingers at Vertex Pharmaceuticals
4:27PM ET 10/03/2019 MT Newswires

Ourania Tatsis, SVP, Cro, sold 632 shares in Vertex Pharmaceuticals (VRTX) for $106,247 on Oct 01, 2019. Tatsis, after the transactions delineated in the...

Vertex Signs Five-Year Deal to Supply Cystic Fibrosis Drugs in Scotland
7:22AM ET 9/12/2019 MT Newswires

Vertex Pharmaceuticals (VRTX) said it has entered into a five-year agreement with Scottish authorities to supply drugs used to treat cystic fibrosis. The...

Analyst Actions: Goldman Sachs Upgrades Vertex to Conviction Buy From Neutral, Lifts PT to $254 From $226
9:14AM ET 9/03/2019 MT Newswires

Vertex Pharmaceuticals' (VRTX) average rating among analysts is a buy, with an average price target of $210. Price: 181.50, Change: +1.48, Percent Change:...

View all Commentary and Analysis

Can Vertex (VRTX) Keep the Earnings Surprise Streak Alive?
9:10AM ET 10/14/2019 Zacks

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right...

Can Vertex (VRTX) Keep the Earnings Surprise Streak Alive?
9:10AM ET 10/14/2019 Zacks

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right...

Can Vertex (VRTX) Keep the Earnings Surprise Streak Alive?
9:10AM ET 10/14/2019 Zacks

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right...

Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
8:30AM ET 10/14/2019 Zacks

Is (VRTX) Outperforming Other Medical Stocks This Year?

Company Profile

Business DescriptionVertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. View company web site for more details
Address50 Northern Avenue
Boston, Massachusetts 02210
Phone+1.617.341.6100
Number of Employees2,500
Recent SEC Filing10/04/20194
Chairman, President & Chief Executive OfficerJeffrey M. Leiden
Chief Financial Officer & Executive Vice PresidentCharles F. Wagner
Chief Scientific Officer & EVP-Global ResearchDavid Matthew Altshuler
Chief Medical Officer & Executive Vice PresidentReshma Kewalramani

Company Highlights

Price Open$172.32
Previous Close$172.41
52 Week Range$151.80 - 195.81
Market Capitalization$44.6 B
Shares Outstanding257.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement10/23/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings20.21
Earnings per Share$8.44
Beta vs. S&P 500N/A
Revenue$3.0 B
Net Profit Margin64.55%
Return on Equity51.71%

Analyst Ratings as of 08/01/2019

Buy
16
Overweight
1
Hold
7
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset